IPP Bureau
Novo Nordisk files FDA application for once-weekly obesity drug CagriSema
By IPP Bureau - December 19, 2025
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
JHS Svendgaard to invest Rs. 25 crore on building new manufacturing unit
By IPP Bureau - December 19, 2025
The new facility is expected to generate 500-600 new jobs in the region
Max Healthcare announces Rs.1,000-cr foray into Pune with 450-bed super speciality hospital
By IPP Bureau - December 19, 2025
The state-of-the-art facility is expected to be commissioned over the next three years
Eli Lilly reports positive Phase 3 results for oral obesity drug Orforglipron
By IPP Bureau - December 19, 2025
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
GenSci, RTW & Yarrow Bioscience strike $1.365 billion global deal for breakthrough graves’ disease therapy
By IPP Bureau - December 19, 2025
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
Agilent Technologies opens India Refurbishment Center
By IPP Bureau - December 19, 2025
The center will deliver Certified Pre-Owned instruments restored to factory-grade standards and backed by Agilent Standard Warranty
,_Thyrocare.jpg "Thyrocare appoints Dr Ramesh Kinha as COO")
Thyrocare appoints Dr Ramesh Kinha as COO
By IPP Bureau - December 19, 2025
Dr Kinha is a seasoned healthcare and diagnostics leader with over 17 years of experience across leading organisations in the diagnostics sector, with deep expertise in laboratory operations and quality systems
Lupin receives positive CHMP opinion for biosimilar Ranibizumab
By IPP Bureau - December 18, 2025
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Biocon Biologics honored as 2025 Asia IP Elite by IAM for 9th consecutive year
By IPP Bureau - December 18, 2025
This recognition demonstrate excellence in intellectual property (IP) value creation.
AstraZeneca India receives permission from CDSCO for Datopotamab Deruxtecan powder
By IPP Bureau - December 18, 2025
The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India
Godavari Biorefineries launches US biotech arm to advance novel cancer therapies
By IPP Bureau - December 18, 2025
The move strengthens GBL’s clinical-stage presence in the United States
Merck’s KEYTRUDA–Padcev combo delivers survival gains in Phase 3 bladder cancer trial
By IPP Bureau - December 18, 2025
Astellas & Pfizer report breakthrough Phase 3 results in muscle-invasive bladder cancer
By IPP Bureau - December 18, 2025
The combination also outperformed chemotherapy on another important secondary endpoint
FDA nod to Johnson & Johnson’s AKEEGA for aggressive prostate cancer
By IPP Bureau - December 18, 2025
Patients with BRCA mutations often face aggressive disease and poor prognosis
Eli Lilly re-elects Nobel Laureate Carolyn Bertozzi to Board
By IPP Bureau - December 17, 2025
Bertozzi currently serves as the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor at Stanford University, and Investigator of the Howard Hughes Medical Institute
